SAP (NYSE:SAP) has successfully warded off a potential multi-billion euro antitrust fine after European Union regulators formally accepted a package of commercial concessions designed to lower costs and boost freedom of choice for enterprise customers.
Honeywell Aerospace (NASDAQ:HONA) is aggressively expanding its development of military systems designed entirely without restricted U.S. technologies, positioning itself to capture surging European defense spending while bypassing Washington’s strict export control roadblocks.
Greenwich LifeSciences (NASDAQ:GLSI) announced today that the European Medicines Agency (EMA) has completed its regulatory review and approved the use of its commercially manufactured GP2 immunotherapy lot for the ongoing Phase III FLAMINGO-01 clinical trial.
Triple Flag Precious Metals (NYSE:TFPM) delivered strong operational results for the second quarter of 2026, generating consolidated revenue of US$129.2 million backed by quarterly metal sales of 28,674 gold equivalent ounces (GEOs).
The French competition authority (Autorité de la concurrence) announced on Thursday that its comprehensive investigation into semiconductor giant Nvidia (NASDAQ:NVDA) is drawing to a close.
Fortuna Mining (NYSE:FSM) reported steady production results for the second quarter of 2026, generating 72,217 gold equivalent ounces (GEO) from its portfolio of operational mines across West Africa and Latin America.
U.S. data resilience and cybersecurity provider Rubrik (NYSE:RBRK) announced on Thursday that it will invest more than $500 million over the next five years within the United Kingdom to anchor its regional growth pipeline.
A fragile interim truce between the United States and Iran fractured dramatically over the last 48 hours as both nations exchanged intense rounds of military strikes, threatening to permanently derail diplomatic tracks aimed at a comprehensive regional peace agreement.
MoneyGram has launched a validator on Solana (CRYPTO:SOL) and joined the Solana Developer Platform to build blockchain infrastructure for future payment services.
Ionis Pharmaceuticals (NASDAQ:IONS) and its development partner AstraZeneca (NYSE:AZN) announced today that their Phase 3 CARDIO-TTRansform clinical trial evaluating eplontersen did not meet its primary efficacy endpoint.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
